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a b s t r a c t
Population aging has been occurring as a global phenomenon with heterogeneous consequences in both
developed and developing countries. Neurodegenerative diseases, such as Alzheimer's Disease (AD),
have high prevalence in the elderly population. Early diagnosis of this type of disease allows early
treatment and improves patient quality of life. This paper proposes a Bayesian network decision model
for supporting diagnosis of dementia, AD and Mild Cognitive Impairment (MCI). Bayesian networks are
well-suited for representing uncertainty and causality, which are both present in clinical domains. The
proposed Bayesian network was modeled using a combination of expert knowledge and data-oriented
modeling. The network structure was built based on current diagnostic criteria and input from
physicians who are experts in this domain. The network parameters were estimated using a supervised
learning algorithm from a dataset of real clinical cases. The dataset contains data from patients
and normal controls from the Duke University Medical Center (Washington, USA) and the Center for
Alzheimer's Disease and Related Disorders (at the Institute of Psychiatry of the Federal University of Rio
de Janeiro, Brazil). The dataset attributes consist of predisposal factors, neuropsychological test results,
patient demographic data, symptoms and signs. The decision model was evaluated using quantitative
methods and a sensitivity analysis. In conclusion, the proposed Bayesian network showed better results
for diagnosis of dementia, AD and MCI when compared to most of the other well-known classiﬁers.
Moreover, it provides additional useful information to physicians, such as the contribution of certain
factors to diagnosis.
& 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Global population aging has been one of the main concerns of
the twentieth century with great economic, political and social
consequences. Moreover, dementia is prevalent among the elderly
observed both in developed and developing countries [1]. Demen-
tia is a clinical state characterized by loss of function in multiple
cognitive domains. The most commonly used criteria for diagnosis
of dementia were established by DSM-IV (Diagnostic and Statis-
tical Manual for Mental Disorders) by the American Psychiatric
Association [2].
There are various speciﬁc types of dementia, often showing
slightly different symptoms. The most common is Alzheimer's
Disease (AD), accounting for between 60% and 80% of dementia
cases [1]. AD is a degenerative disease causing lesions in the brain.
Early clinical symptoms of AD are often related to difﬁculty in
remembering new information, and later symptoms include
impaired judgment, disorientation, confusion, behavioral changes
and difﬁculty in speaking and walking.
According to the annual report published by the Alzheimer's
Association [3], patients with AD impact more than 10 million
of health care providers in the United States in 2013. AD was
considered as the sixth-leading cause of death across all ages
groups in the United States. The Alzheimer's Association estimated
in the United States that there will be over 6 million people over
65 years old affected by AD in 2025 [4].
The prevalence of dementia in Latin America is similar to that
reported in developed countries [5]. An epidemiological study
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/cbm
Computers in Biology and Medicine
http://dx.doi.org/10.1016/j.compbiomed.2014.04.010
0010-4825/& 2014 Elsevier Ltd. All rights reserved.
n Corresponding author.
E-mail addresses: fseixas@ic.uff.br (F.L. Seixas),
biancaz@br.ibm.com (B. Zadrozny), jlaks@centroin.com.br (J. Laks),
aconci@ic.uff.br (A. Conci), debora@ic.uff.br (D.C. Muchaluat Saade).
Computers in Biology and Medicine 51 (2014) 140–158
with the Brazilian population estimated a prevalence of dementia
of 8% for the elderly population [6]. The screening tools, assess-
ment and diagnostic criteria applied for such studies are synthe-
sized by Nitrini et al. [5]. Among the diseases causing dementia,
AD was the most frequent in all studies, ranging from 50% to 55%
of all cases.
The diagnosis of individuals with earliest stage of AD motivates
a number of research initiatives [7,8]. Mild Cognitive Impairment
(MCI) is usually associated to a preclinical stage of AD and causes
cognitive impairments severe enough to be noticed by patient's
relatives, or other people, without producing any changes in
patient's daily activities [9]. A deﬁcit in episodic memory is the
most common symptom in MCI patients [10].
An AD incidence study revealed that, annually, 10–30% of
patients who had received an MCI diagnosis converted to AD,
while the conversion rate of normal elderly subjects is 1–2% [11].
The ﬁrst broadly accepted criteria for the clinical diagnosis of
probable AD were established by the NINCDS-ADRDA (National
Institute of Neurological, Communicative Disorders and Stroke -
Alzheimer's Disease and Related Disorders Association) workgroup
[12]. These criteria were revised by the National Institute on Aging
(NIA) and the Alzheimer's Association recently [13], including
advances in medical imaging techniques and biomarkers to sup-
port AD diagnosis, and better understanding of the AD process.
The criteria were published in three documents: the core clinical
criteria of the recommendations regarding all-cause dementia
[14], dementia due to AD [13] and MCI due to AD [10].
Regarding healthcare services, there is a growing global con-
cern about patient safety and healthcare system effectiveness [15].
In the same way, diagnostic errors are an important source of
preventable harm to health systems [16]. A diagnostic error can
be deﬁned as a diagnosis that is missed, wrong, or delayed, as
detected by some deﬁnitive test or ﬁnding. The awareness and
understanding of medical errors have promoted safer health care
through health information systems solutions [17]. Clinical deci-
sion support systems (CDSS) are considered as an important
category of health information systems designed to improve
clinical decision-making [18]. Characteristics of individual patients
are matched to characteristics from a knowledge base, and an
algorithm generates patient-speciﬁc assessments or recommenda-
tions. Studies have indicated that CDSS can reduce diagnostic error
rates [19].
This paper proposes a Bayesian Network (BN) decision model
for supporting the diagnosis of dementia, AD and MCI. The
proposed BN can be used for building clinical decision support
systems (CDSS) to help in the diagnosis of such diseases. BNs are
well-suited for representing uncertainty and causality, which
are both present in the clinical domain. The proposed BN
was modeled using a combination of expert knowledge and
data-oriented modeling. The network structure was built based
on current diagnostic criteria and input from physicians who are
experts in this domain. The network parameters were estimated
using a supervised learning algorithm from a dataset of real
clinical cases. In this text, we deﬁne an instance as an ordered list
of values representing a set of observations of a patient. Such
observations include symptoms, signs and results of neuropsycho-
logical exams of patients, and normal controls from the Duke
University Medical Center (Washington, USA) as well as the Center
for Alzheimer's Disease and related disorders, at the Institute of
Psychiatry of the Federal University of Rio de Janeiro (Rio de
Janeiro, Brazil). We deﬁne an attribute as a labeled element (or
observation) of an instance.
The next sections are organized as follows. Section 2 discusses
CDSS and related work. Section 3 describes some concepts of
Bayesian networks, including the Bayesian learning methods and
the inference algorithms. Section 4 shows the process used to
build the BN model, the dataset of patients and normal controls
used for training and the proposed BN. In Section 5, we show the
experimental results. Section 6 discusses the results. Finally, in
Section 7, we present conclusions and directions for future work.
2. Clinical decision support systems and related work
CDSSs are computational systems designed to support high-level
cognitive functions involving clinical diagnosis, such as reasoning,
decision-making and learning [20]. Wright et al. [21] provided a
taxonomic description of CDSS, grouping them according to their
purpose regarding clinical activities, including prevention and
screening, drug dosing, chronic disease management, diagnosis
and treatment, considering patients from both outpatient and
inpatient settings. CDSS can be designed for a number of user
proﬁles, including physicians, general practitioners, nurses, or even
patients seeking prevention or other health-related behaviors.
CDSSs are also grouped by their prevailing inference engine,
including rule-based systems, clinical guideline-based systems
and semantic network-based systems [22]. Rule-based systems
use simple conditional expressions (e.g., if-then-else clauses) for
making deductions and aiding clinical decisions. Guideline-based
systems indicate the most likely clinical decision or pathway
from a set of predetermined options, guided by a workﬂow that
describes, for example, diagnosis rules or a treatment process.
Semantic network-based systems use semantic relations between
concepts to perform an inference algorithm. BN-based CDSSs fall
into the semantic network category, since BN nodes represent
clinical concepts, and edges (or arcs) represent causal relations.
Fig. 1 depicts some CDSSs found in the literature and their
prevailing inference engine. In the next paragraphs, we comment
Fig. 1. Clinical Decision Support Systems (CDSSs) grouped by their inference engine.
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some CDSSs, focusing on BN-based ones, and conceptually com-
pare their decision models to ours.
Table 1 lists some CDSSs grouped also by their prevailing
inference engine and their corresponding disease domain. The
earliest CDSSs were rule-based, such as CASNET [23], Internist-I
[24], and MYCIN [25] and CPOL [26]. CASNET and MYCIN were
developed for aiding the diagnostic of Glaucoma and Meningitis,
respectively, and Internist-I and CPOL, for aiding the diagnostic of
diseases of various domains. Korb and Nicholson [27] provided an
exhaustive list of CDSSs applied to different areas. Some of those
CDSSs are described in the following paragraphs.
QMR (Quick Medical Reference)/Internist-I is one of the earliest
systems using an inference engine based on BN. A BN is a
probabilistic graphical model that represents a set of random
variables and their conditional dependencies via a directed acyclic
graph (DAG) [48]. QMR/Internist-I used a BN with two-level
structure representing the probabilistic relationships between
diseases and symptoms [49]. The conditional probabilities of
symptoms and diseases were estimated by combining probabil-
ities from disease proﬁles and statistical data from hospitals [50],
deriving statistical parameters from health information systems
and the judgment of human experts from the corresponding
disease domain. Furthermore, QMR used a noisy-OR model,
described by Pearl [48], to simplify the conditional probability
estimation and expert elicitation. Hence, based on given symp-
toms, the network can be used to compute the probabilities of the
presence of various diseases by a suitable inference engine,
supporting the physicians in their diagnostic process. One version
of QMR network described by Pradhan et al. [51] included back-
ground nodes, which they called predisposing factors, needing
prior probabilities, while the remaining nodes required probabil-
ities to be assessed for each of their values. Thus, we called
such Bayesian structure a three-level structure, where each level
represents (1) background information, (2) diseases and (3) symp-
toms, signs and neuropsychological test results, respectively, as
depicted in Fig. 2. One difﬁculty of using such modeling structure
is that of estimating the conditional probabilities that reﬂect real
clinical cases and, at the same time, meeting the random variables
independence assumption from the noisy-OR model [52].
Mentor is a CDSS to predict mental retardation in newborns
[37]. That system is based on a BN whose structure was discovered
from data using an algorithm proposed by [53] and validated by
domain experts.
DiaVal is a CDSS for diagnosis of cardiovascular diseases using a
BN [38]. The BN structure was built by domain experts using a causal
representation of the cardiac pathophysiology and, afterwards, they
incorporated some results, mainly from echocardiography.
Sakellaropoulos and Nikiforidis [39] used a BN with discrete
probability distribution for the assessment of prognosis after 24 h
for patients who had head injuries. The BN structure and para-
meters were learned from cases of patients and the prognosis
results were compared to those made by an expert. They achieved
a BN success rate closer to the success rate of the expert. Burnside
Table 1
Clinical decision support systems.
Inference engine Name Disease domain Reference
Rule-based systems CASNET Glaucoma Weiss et al. [23]
Internist-I 572 diseases linked to more than 4000 symptoms Miller et al. [24]
MYCIN Meningitis Buchanan and Shortliffe [25]
unnamed 257 mental disorders Amaral et al. [28]
CPOL Diabetes, cardiac diseases and respiratory disorders Beliakov and Warren [26]
unnamed Alzheimer's disease using SPECT (Single-Photon Emission Computed
Tomography) images and classiﬁer based on SVM (Support Vector Machine)
Salas-Gonzalez et al. [29]
unnamed Alzheimer's disease using fMRI (functional Magnetic Resonance Image)
and classiﬁer based on PCA (Principal Component Analysis)
Tripoliti et al. [30]
Clinical guideline-based
systems
EON Hypertension Musen et al. [31]
Asbru Diabetes, jaundice, breast cancer Shahar et al. [32]
GLIF Depression, diabetes and hyperglycemia Peleg et al. [33]
Prodigy Chronic diseases, including asthma and hypertension Johnson et al. [34]
Proforma Not speciﬁed. Fox et al. [35]
KON3 Oncology Ceccarelli et al. [36]
Semantic network-based
systems
QMR Internist-I 572 diseases linked to more than 4000 symptoms Miller et al. [24]
Mentor Mental retardation in newborns Mani et al. [37]
DiaVal Cardiovascular diseases Diez et al. [38]
Unnamed Head-injury Sakellaropoulos and Nikiforidis [39]
Unnamed Mammography Burnside et al. [40]
Unnamed Pneumonia Aronsky and Haug [41]
Unnamed Mild cognitive impairment using MRI
(Magnetic Resonance Image) and neuropsychological assessments
Yan et al. [42]
Promedas 2000 diseases linked to 1000 symptoms Wemmenhove et al. [43]
BayPAD Pulmonary embolisms Luciani et al. [44]
PDS Pediatric diseases described in ICD-10
(International Classiﬁcation of Diseases – release 10)
Pyper et al. [45]
IMASC Cardiac diseases Czibula et al. [46]
TiMeDDx Infectious and noninfectious diarrhea Denekamp and Peleg [47]
Q2
F1 F2 Fj
B1 B2 Bn
1st level: background 
information
2nd level:
query nodes
3rd level: symptoms, 
signs, tests results
Q1 Qm
...
...
...
Fig. 2. Three-level Bayesian network structure.
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et al. [40] built a BN for aiding radiologists in their decision-
making, integrating mammogram ﬁndings using BI-RADS (Breast
Imaging Reporting and Data System), a standardized lexicon
developed for mammography. Their BN model provided probabil-
ities associated to benign, pre-malignant and malignant breast
cancer disease. Aronsky and Haug [41] showed the modeling and
the evaluation of a BN for the diagnosis of pneumonia.
Although using a BN structure similar to QMR, Promedas [43]
used as an inference engine a novel method called Loop Corrected
Belief Propagation (LCBP) [54] described in Section 3.2.
BayPAD (Bayes Pulmonary embolism Assisted Diagnosis) used a
BN for diagnosis of pulmonary embolisms [44]. The BN structure
was constructed from expert elicitation and the conditional
probabilities estimated from patient data provided by PISA-PED
(Prospective Investigative Study of Acute Pulmonary Embolism
Diagnosis). In order to improve the model accuracy, the results
were reviewed using the Cox Regression-Calibration Model [55].
PDS (Pediatric Decision Support system) is a BN-based CDSS
deployed at the Children's Hospital of Eastern Ontario [45]. The
system allows a resident physician to deﬁne a patient's case based
on symptoms and generates a list of possible diagnoses based on
the World Health Organization. The BN structure was manually
built based on expert elicitation and BN conditional probabilities
were estimated using a set of patient cases.
IMASC (Intelligent MultiAgent System for Clinical Decision
Support) is a CDSS for diagnosis of cardiac diseases using the
artiﬁcial neural network (ANN) [46]. Considering the contribu-
tions, the IMASC extends the intelligent agent concept, sharing
messages among other agents in a modular approach.
In TiMeDDx [47], the BN was modeled using a main clinical
manifestation or MCM-oriented model. MCM-oriented diagnosis
is a problem-oriented process that starts with a chief clinical
problem, reasons about possible diagnoses that would be mani-
fested as MCM, and suggests the clinical data items that should be
collected in order to differentiate among alternative diagnoses. Its
BN was built based on expert elicitation.
Yan et al. [42] used a BN for classifying patients with MCI using
Magnetic Resonance Images (MRI) and other demographic and health
data from patients. The BN structure was discovered using a greedy
search algorithm.
Another popular technique for constructing decision models
is applying multicriteria decision aiding (MCDA) methods. MCDA
involves a set of methods for aggregation of multiple evaluation
criteria to one or more potential actions [56]. There are conceptual
similarities between MCDA approaches and Bayesian learning meth-
ods. Both perspectives consider the problem of learning a decision
from data as a maximization of an empirical utility function [57]. In a
Bayesian learning perspective, the utility function can be maximizing
some Bayesian Estimation score, like Maximum-Likelihood Estimation
(MLE) [27]. MLE score will be described in Section 3.1.
There are works that propose integrating approaches based on
MCDA and statistical learning methods, i.e., the implementation
of MCDA concepts in a statistical learning framework and the
development of hybrid methodologies. Castro et al. [58] showed
an MCDA approach called MACBETH (Measuring Attractiveness by
a Categorical Based Evaluation Technique) integrated with a BN.
Their decision model aims at showing what assessment items
from neuropsychological batteries are more attractive given the
CDR (Clinical Dementia Rating) scale result. They used an extended
discrete BN with utility and decision nodes, so-called Inﬂuence
Diagram [59]. An Inﬂuence Diagram is a generalization of a BN, in
which not only probabilistic inference problems but also decision-
making problems can be modeled and solved. The utility
nodes represent a set of objectives or preferences considered by
a decision-maker. The decision nodes represent a set of outgoing
branches considered in a decision-making process. In an MCDA
approach, BN nodes represent the internal or external factors
that can affect the decision criteria. Their BN structure allowed
calculating the conditional probability tables (CPTs) of BN nodes
from dataset without applying a complex statistical learning
method. Their dataset is composed by patient cases set, where
each attribute is related to an assessment item from neuropsycho-
logical batteries. In addition, missing attribute values were treated
as a discrete state, being replaced by a hypothetical value. In our
BN modeling, we address a different treatment for missing
attribute values, as described in Section 3.1.
Menezes et al. [60] proposed a hybrid model combining MCDA
and BN for diagnosis of Diabetes type 2. Pinheiro et al. [61] used a
similar approach and showed a ranking model based on MCDA
and BN for aiding the diagnosis of AD. Their objective indicates
what assessment patient items have the highest impact for
determining the AD diagnosis. Their BN was manually built, where
the Bayesian nodes were semantically related to each assessment
item. Assessment items were composed by neuropsychological
batteries provided by CERAD [62].
Instead of considering each neuropsychological question sepa-
rately, our work used ﬁnal neuropsychological test results. We
designed a decision model to predict AD diagnosis, and other
related diseases, such as dementia and MCI. Our decision model
allows indicating the most relevant items based on a sensitive
analysis instead of MCDA.
Furthermore, our CDSS differs from other BN-based CDSSs in
terms of BN structure building and its parameter estimation. QMR
and Promedas used a manually built structure oriented by the
three-level structure proposed by Pradhan et al. [51]. BayPAD, PDS
and TiMeDDx also have a BN structure manually built based on
domain expert elicitation, but they did not use the three-level
structure template described before. In contrast, the BN structure
designed for Mentor was automatically discovered from data.
Regarding BN parameter estimation, QMR and TiMeDDx have
probability distribution estimated by a domain expert. Other BN-
based CDSSs use some learning algorithm from data to estimate
the BN parameters. In contrast, our CDSS has a BN structure
oriented by Pradhan's three-level structure template, which was
manually built with the support of domain experts. In addition to
that, our BN parameter values are estimated using a Bayesian
learning method that is described in Section 3.1.
Fig. 3 depicts some components of the CDSS described in this
paper. The knowledge base contains the BN in which each node is
associated to a clinical concept from the diagnosis criteria of the
disease of interest. The inference engine estimates the posteriori
probability distribution of non-evidence random variables, namely
variables that are not observed in the patient dataset. Each
BN random variable must be associated to a concept from the
healthcare domain, including demographic data. The patient
dataset is used to estimate the BN conditional probabilities by a
supervised learning algorithm. Each patient dataset attribute must
also be associated to a healthcare concept during the BN modeling
phase. The supervised learning results and BN performance
measures are evaluated by a system analyst.
The patient clinical data are commonly stored in a Health
Information System (HIS) using an Electronic Health Record (EHR)
model. A BN evidence is derived from the matching between the
healthcare concept assigned to the patient clinical datum and the
concept assigned to the BN random variable. Hence, both concept
domains must be the same for system interoperability. The CDSS
results can be viewed through HIS's user interface, indicating the
most probable diagnosis and the most sensitive non-observed
items that should be evaluated by the physician, in order to
conﬁrm or refute an initial diagnosis hypothesis.
In the next section, we will describe some BN concepts used in
this work.
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3. Bayesian network concepts
BNs represent a domain in terms of random variables and
explicitly model the interdependence between them [63]. BNs are
graphically represented by directed acyclic graphs (or DAGs),
whose nodes represent random variables and arcs express direct
dependencies. In our BN model, we consider only discrete random
variables. Suppose Xi is the ith random variable containing ri
discrete states. Also suppose that Xik is the kth state of random
variable Xi. Consider a BN containing a set of nodes or random
variables XG ¼ 〈X1;X2;…;XN〉, a pair 〈G;Θ〉, where G represents a
DAG and Θ the set of conditional probabilities variables Θ¼ 〈θijk :
8 ijk〉. θijk is called the joint probability, i.e., θijk ¼ PrðXi ¼ xki jpa
ðXiÞ ¼ pjiÞ where pij represents the parent (pa) node set of Xi from G
and pij the jth combination of parent nodes of Xi.
A Bayesian network modeling involves a number of computa-
tional algorithms. Bayesian learning algorithms are commonly
applied to discover the Bayesian structure and/or estimate para-
meter values from data. The structure and parameters necessary
for characterizing a BN can be provided either by experts, or
by automatic learning from a dataset. Section 3.1 describes the
Bayesian learning methods and compares them to different
approaches. The Bayesian inference algorithm is responsible for
calculating marginal probabilities, given an evidence set. Section
3.2 lists some Bayesian inference algorithms.
3.1. Bayesian parameter learning
The BN learning task can be divided into two subtasks:
structural learning and parametric learning, i.e., the estimation
of the numerical parameters (conditional probabilities) for a given
BN structure. A number of different methods were proposed
for estimating a BN from a dataset. Such methods are usually
classiﬁed into two approaches: constrained-based methods and
scored-based methods. A well-known constrained-based method
is the Peter–Clark (PC) algorithm used for discovering BN structure
[64]. Scored-based methods have two major components: a
scoring metric that measures every candidate BN using a score
function with respect to a dataset, and a search procedure to move
through a solution space composed by possible BNs. Examples of
such learning methods are Expectation-Maximization (EM) algo-
rithm [65], evolutionary algorithms [66], Gibbs sampling based
algorithms [67].
We used a BN model whose structure is known and parameters
(conditional probabilities) are unknown. Thus, we used the EM
algorithm for parametric learning. EM mainly differs from evolu-
tionary algorithms in its searching method, i.e., EM uses an
ascendant gradient algorithm, while evolutionary algorithms
use genetic algorithms. EM differs from Gibbs sampling in the
following aspects: EM is a deterministic algorithm and converges
in Maximum-Likelihood, while Gibbs sampling is a non-deter-
ministic method and converges towards a posterior distribution.
Nevertheless, all these learning methods are relatively similar.
Given a data set D¼ ðD1;…;DMÞ, where DiARd composed by M
independent and identically distributed observations from a dis-
tribution PrðDjθÞ. Let a BN node represents a random variable X
with R discrete states or multiple values. So, the Bayesian para-
meter learning consists of estimating parameter set θ¼ ðθ1;…;θRÞ
that best represents data. The parameters that best represents a
dataset is known as θMLE , where MLE stands for Maximum Like-
lihood Estimation, whose equation is shown below:
θMLE ¼ arg max
θAΘ
PrðDjθÞ ð1Þ
Let θi ¼ PrðD¼ xiÞ. Suppose in a dataset D there are mi instances
where D takes value xi. Then, the multinomial likelihood is
LðθjDÞ ¼ PrðDjθÞ ¼ ∏
N
j ¼ 1
PrðDjjθÞ ¼ ∏
r
i ¼ 1
θmii ð2Þ
The conjugate family for multinomial likelihood is a Dirichlet
distribution. A Dirichlet distribution is parametrized by R hyper-
parameters α1;…;αR. So, assuming as prior probability a Dirichlet
distribution, the posterior probability PrðθjDÞ is given by
PrðθjDÞ  ∏
R
i ¼ 1
θαi þmi 1i ð3Þ
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where αiþmi are parameters from Dirichlet distribution Dirðα1þ
m1;…;αRþmRÞ.
Let us assume that
θiMLE ¼
mi
m1þm2þ⋯þmR
ð4Þ
In the case of a BN with discrete distribution that contains
N nodes or random variables X1;…;XN , number of states of
Xi : 1;2;…; ri, number of conﬁgurations of parents (pa) of Xi :
1;2;…; qi, so the parameters to be estimated are θijk ¼ PrðXi ¼
jjpaðXiÞ ¼ kÞ, i¼ 1;…;n; j¼ 1;…; ri; k¼ 1;…; qi in general BNs:
θijkMLE ¼
αijkþmijk
∑jαijkþmijk
ð5Þ
Eq. (5) is used to compute θ parameters for BN. However, if the
dataset contains instances with partial observations, i.e., attributes
with missing values, it will be necessary to use a more appropriate
learning method. Missing attribute values (partial observations)
are caused by a number of reasons, either the patient might not
have performed such neuropsychological test, or the physician
might not have included such results in the dataset. A parametric
learning method usually applied in the case of partial observations
is the EM algorithm [68]. EM is an iterative algorithm, which tries
to maximize θMLE at each iteration. The algorithm contains two
steps: E-Step computes a posterior distribution over Di using a BN
inference engine and the M-step maximizes the log-likelihood
from a Dirichlet distribution using a Newton-based (or other
ascendant gradient) algorithm detailed by Minka [69].
Some approximation methods for EM, as the MCMC algorithm
(Markov Chain Monte Carlo) [70], try to reduce the computational
cost for Bayesian learning. We did not use any approximation
method because our BNs are fairly small in terms of the amount of
nodes and their corresponding parents, which makes the compu-
tational cost irrelevant.
The parameters for the EM algorithm are the training set D and
the Dirichlet initial hyperparameters set α. We considered α¼ 1
for all attributes, assuming a prior uniform distribution, or non-
informative priors [71]. The routine goes on until it reaches the
convergence or stopping criterion. As a result of the iterative
process, we reach θMLE . We used the EM implementation available
in the BN toolbox developed in Mathworks Matlab& [72].
3.2. Bayesian inference engine
A Bayesian inference engine computes the posterior probability
distribution, as shown in Eq. (6) in terms of θi0 j0 , admitting a
statistically independent distribution θij with ith random variable
and jth combination of parent node of θi0j0 , and G representing a
DAG.
Prðθi0 j0 jGÞ ¼ ∏
N
i ¼ 0
∏
qi
j ¼ 1
PrðθijjGÞ; ð6Þ
where N is the number of BN nodes, qi is the number of
combination of parent nodes from θi0j0 .
Our interest is computing the marginal probabilities of the
query node. The query node is a BN node that represents the
diagnosis for a disease, as shown in Fig. 2 (nodes Qi). Such
probabilities can be either positive or negative for diagnosis of
the disease of interest. There are inference engines that use exact
methods and approximate methods. Furthermore, approximate
methods can be deterministic or stochastic. The most suitable
algorithm will depend on the computational cost and accuracy
level required.
Junction Tree (JT) [63] is a message passing algorithm for
performing inference on graphical models, such as BNs. In contrast
to other inference algorithms, JT transforms the BN to a junction
tree representation to perform an exact inference.
Belief Propagation (BP) [73] is also a message passing based
algorithm that operates on a factor graph. A factor graph is a
bipartite graph with nodes, factor nodes, and an edge between
variables and factors. BP produces exact results on tree-like factor
graphs. However, if the factor graph contains one or more loops,
results are approximate. A novel algorithm proposed a method
that corrects BP for the presence of loops in the factor graph and
obtains improvements in accuracy using a loop expansion scheme
called Loop Correct Belief Propagation (LCBP). LCBP is used in cases
which the error becomes unacceptable [54]. In short, LCBP
removes a node from the graph and factorizes the probability
distribution on its neighbors, so-called cavity distribution. For
more details see [43].
Since our discrete BNs are simple as previously mentioned, we
used JT as an inference engine.
4. Bayesian network modeling
As mentioned in Section 1, the training dataset used in our
work for Bayesian learning was composed by normal controls and
patient cases set provided by two Institutions: CERAD (Consortium
to Establish a Registry for Alzheimers Disease) of Duke University
Medical Center (Washington, USA) [62], and CAD (Center for
Alzheimer's Disease and related disorders) of Federal University
of Rio de Janeiro (Rio de Janeiro, Brazil) with the consent of the
ethics committee for medical research, project identiﬁcation
number 284/2010.
Table 2 lists the selected attributes of the CERAD dataset. The
cited neuropsychological tests are detailed at http://cerad.mc.
duke.edu/ (visited at February 22th, 2014). Table 3 lists the
selected attributes of the CAD dataset.
Table 4 shows the number of cases from both training datasets.
CERAD's dataset contains patients diagnosed with dementia and
AD composing two subsets. The dementia subset is composed of
normal control subjects and patients with dementia. The AD
subset is composed of patients previously classiﬁed as positive
for dementia. The patients from the AD subset can be positive for
AD or negative. Thirty cases from the AD subset (CERAD) had the
diagnosis not classiﬁed. The MCI subset is composed of patients
previously classiﬁed as negative for dementia. The patients from
the MCI subset can be either positive or negative for MCI.
As shown in Table 4, because some subsets were unbalanced
(e.g. the number of negative cases was much smaller than the
number of positive cases), we applied a balancing technique called
SMOTE (Synthetic Minority Oversampling Technique) for over-
sampling the negative cases without modifying the training
dataset characteristics [74].
As mentioned in Section 3.1, we have some attributes in both
datasets with missing values. The attributes with completely
missing values were removed from both datasets. We also used
a ﬁlter based on information gain score to remove attributes of
datasets that have score values below a threshold [75]. We used
information gain implementation available on WEKA1 (Waikato
Environment for Knowledge Analysis), a popular suite of machine
learning software. The information gain score is between 0 and 1.
The attributes with information gain score below 0.0001 were
rounded to zero by WEKA and thus removed from both datasets.
The attributes of both datasets showed before (Tables 2 and 3)
1 http://www.cs.waikato.ac.nz/ml/weka/.
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Table 2
List of CERAD dataset selected attributes.
Levela Attributeb Statesc Diagnosisd
D AD
D Dementia 1:negative; 2:positive
D Alzheimer's Disease (AD) 1:negative; 2:positive
B Education 1:[0–9]; 2:[10–16]; 3:[17–19]; 4:[20–inf]
F Clinical Dementia Rating (CDR) scale 1:0; 2:0.5; 3:1; 4:2; 5:3; 6:4; 7:5
B Ethnicity 1:caucassian; 2:afrodescendent
F Mini Mental State Exam (MMSE) score 1:[0–27]; 2:[28–30]
F Boston naming 1:[0–14]; 2:[15–inf]
F Short Blessed score 1:[0–5]; 2:[6–inf]
F Cognitive impairment reported by patient or informant 1:negative; 2:positive
F Activities for Daily Living (ADL) score 1:0; 2:0.5; 3:1; 4:2
F Recall Word List score 1:0; 2:40
B Cerebrovascular disease 1:negative; 2:positive
F Difﬁculties in the use of language elements 1:without difﬁculty; 2:mild difﬁculty; 3:moderate difﬁculty
B Gender 1:male; 2:female
F Gradual decline of cognitive functions 1:negative; 2:positive
F Verbal ﬂuency 1:negative; 2:positive
F Functional abilities 1:negative; 2:positive
F Changes in personality and behavior 1:negative; 2:positive
F Word List Recognition score 1:0; 2:40
F Memory Word List score 1:0; 2:40
F Primary progressive aphasia 1:negative; 2:positive
a B¼Background information; D¼Disease of interest; F¼Findings. Attributes classiﬁed as Background information are located at the 1st level of BN. Attributes classiﬁed
as Findings are located at the 3rd level of BN.
b Each selected attribute was assigned to a BN random variable. Attributes can represent symptoms, signs, neuropsychological tests, demographic data and predisposal
factors.
c Represent the possible discrete states that random variable can assume. The syntax for some multinomial attributes is N:[J–K], where N¼multinomial value, J¼ lower
limit of interval; K¼upper limit of interval. Inf¼ inﬁnite. The limit values were estimated by the discretization algorithm used.
d If the attribute was selected for Dementia (D) subset or Alzheimer's disease (AD) subset.
Table 3
List of CAD dataset selected attributes.
Levela Attributeb Statesc
D Dementia 1:negative; 2:positive
D Alzheimer's Disease (AD) 1:negative; 2:positive
D Mild Cognitive Impairment (MCI) 1:negative; 2:positive
F Mini Mental State Exam (MMSE) score D and AD: 1:[0-17]; 2:[18-26]; [27-30] MCI: 1:[0-28]; 2:[29-30]
F Clinical Dementia Rating (CDR) scale 1:0; 2:0.5; 3:1; 4:2; 5:3
F Pfeffer questionnaire score D and AD: 1:0; 2:[1-2]; 3:[3-inf]
MCI: 1:[0-1]; 2:[2-3]; 3:[3-inf]
F Verbal Fluency Test (VFT) score D and AD: 1:[0-4]; 2:[5-11]; 3:[12-inf] MCI: 1:[0-15]; 2:[16-inf]
F Clock Drawing Test (CDT) scale 1:0; 2:1; 3:2; 4:3; 5:4; 6:5
F Trial Making Test (TMT) score D and AD: 1:[0-16]; 2:[17-59]; 3:[60-inf] MCI: 1:[0-36]; 2:[37-inf]
B Age D and AD: 1:[0–72]; 2:[73–inf]
MCI: 1:[0–69]; 2:[70–inf]
F Lawton scale D and AD: 1:[0–9]; 2:[10–inf]
MCI: 1:[0–14]; 2:[15–inf]
F IQCode (Informant Questionnaire on Cognitive Decline in the Elderly) D and AD: 1:[0–3.55]; 2:[3.56–inf]
MCI: 1:[0–3.32]; 2:[3.33–inf]
F Stroop color word test score D and AD: 1:[0–15]; 2:[16–inf]
MCI: 1:[0–17]; 2:[18–inf]
F Berg balance scale D and AD: 1:[0–51]; 2:[52–inf]
MCI: 1:[0–54]; 2:55; 3:[56–inf]
B Gender 1:male; 2:female
F Depression 1:negative; 2:positive
B Education D and AD: 1:[0–13]; 2:[14–inf]
MCI: 1:[0–15]; 2:[16–inf]
a B¼Background information; D¼Disease of interest; F¼Findings. Attributes classiﬁed as Background information are located in the 1st level of BN. Attributes classiﬁed
as Findings are located in the 3rd level of BN.
b Each selected attribute was assigned to a BN random variable. Attributes can represent symptoms, signs, neuropsychological tests, demographic data and predisposal
factors.
c Represent the possible discrete states that random variable can assume. The syntax for some multinomial attributes is N:[J–K], where N¼multinomial value, J¼ lower
limit of interval; K¼upper limit of interval. inf¼ inﬁnite. The limits values were estimated by the discretization algorithm used.
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were ordered by information gain score. We also removed attri-
butes with missing values ratios greater than 70%. Values below
such limit have measure of conﬁdence within expected [76]. We
carried out all those attribute ﬁlters aiming at improving the
Bayesian learning algorithm performance.
The dataset attributes have data with numerical (or contin-
uous) and multinomial (or binomial) types. Since the Bayesian
learning algorithm and the inference engine used for modeling our
BN are suitable for discrete random variables, those attributes
values are converted to multinomial or binomial data types.
Furthermore, some Bayesian classiﬁers have difﬁculty in dealing
with continuous variables [77]. Using an objective function
and a search algorithm, the discretization algorithm estimates
the cutting points for numerical attributes, splitting them into
well-deﬁned numerical ranges covering the whole numerical
domain. We used the discretization algorithm based on MDL
(Minimum Description Length) described by Kononenko [78],
using its implementation in WEKA.
We used a data-oriented approach as BN modeling. Fig. 4
shows the BN modeling process using BPMN (Business Process
Modeling Notation)2 workﬂow notation. The process starts with
mapping the diagnosis criteria guideline for the disease of interest.
Due to the data-oriented approach, the BN depends on the
attributes from patients' case set. Furthermore, the healthcare
concepts from diagnosis criteria are compared to concepts from
BN random variables. The objective is building a BN decision
model as close as possible to the diagnosis criteria. Then, the
training dataset is preprocessed, in order to ﬁlter the attributes
with high missing values ratio, or those that are not relevant for
the diagnosis. After that, the BN is manually built with parameters
estimated by a supervised learning algorithm from data. Then,
the Bayesian learning is evaluated based on well-established
performance metrics. If the performance measures are acceptable,
the BN is modeled and ready to use. Otherwise, a System Analyst
should review the BN. A decision model review is triggered
whenever a domain expert or physician needs to add new ﬁndings
to the decision model, or repeats the BN learning algorithm using a
more complete patients' cases set.
Fig. 5 shows the diagnosis guideline for dementia, AD and MCI,
represented also using BPMN notation. In a ﬁrst moment, the
general practitioner asks the patient about his/her clinical history
and carries out clinical tests or exams for dementia screening. If
the patient has possible dementia, the physician carries out a
number of neuropsychological tests, to conﬁrm the initial hypoth-
esis of dementia. If the diagnosis of Dementia is conﬁrmed, the
Table 4
Patients' cases datasets.
Institution Diseases Dementia AD MCI
Diagnosis Na P N P U N P
CERAD Number of cases 463 1094 502 562 30 – –
Number of cases after applying the oversampling technique for balancing the base 926 1094
Missing values ratiob 48% 44% 47% 42% – – –
CAD Number of cases 67 180 45 135 – 35 32
Number of cases after applying the oversampling
technique for balancing the base
134 180 90 135 –
Missing values ratio 29% 24% 29% 22% – 37% 21%
a N¼negative; P¼positive; U¼unclassiﬁed.
b The missing values ratio was calculated dividing the total of missing attribute values by the number of instances multiplied by the number of attributes of the
corresponding subset. The number of attributes was obtained by counting the remaining attributes after applying the attributes ﬁlter.
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Fig. 4. Bayesian network modeling process.
2 http://www.bpmn.org.
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physicianwill carry out neuropsychological test batteries for AD, to
investigate if the dementia is due to AD. Otherwise, the physician
will carry out tests for MCI.
As shown in Fig. 5, since the decisions related to diagnosis are
made in a non-concurrent way and at different time, we designed
one BN for supporting each decision-making procedure. So, in
contrast to Fig. 2, each BN has one target node. An interpretation of
marginal probability distribution of the target node can indicate
the uncertainty about a diagnosis. For example, if probability
values are equilibrated (e.g. 50% for negative and 50% for positive
diagnosis, respectively), one can consider such distribution as a
maximum uncertainty. The uncertainty can be reduced by gather-
ing more data from the patient, making them BN evidences.
In our BN model, we also included a utility node linked to the
BN target node, and a decision box linked to the utility node,
transforming such model into an Inﬂuence Diagram. As a decision
model, the utility function purpose is modeling the relative cost to
both healthcare system and patient's health perspectives, of a
false-positive and false-negative diagnosis. We used symmetric
values as parameters for the utility function. This point can be
reviewed in a future work.
The Bayesian inference is based on statistical independence of
Xi, given its parent node set, where Xi is the ith node from G.
Hence, we evaluated the independence between two sets of
attribute data associated with random variables that have the
same parent node. A quantitative measure for evaluating the
statistical independence is the correlation coefﬁcient. As it
approaches zero, they are closer to uncorrelated, meaning data
independence. The closer the coefﬁcient is to either 1 or 1, the
stronger the correlation between the attribute data, meaning data
dependence.
In the case of apparent dependence between a pair of nodes
with a common parent node was identiﬁed, there might be a
causal connection between them. As a result, the BN structure
should be reviewed and an edge should be inserted between them.
Fig. 6 shows the box plot of correlation coefﬁcient distribution
evaluated in pairs. The box plot is a graphical representation of
data that shows a dataset's lowest value, highest value, average
value, and the values of ﬁrst and third quartile. In CERAD, most
values were focused on zero, meaning that the attribute data
are fairly independent. In CAD, values varied widely around
zero, meaning that the attribute data are moderately indepen-
dent. Despite both datasets having almost the same amount of
attributes, CERAD has a number of instances signiﬁcantly higher
than CAD. Furthermore, we noticed some outliers in the box plot
of both datasets, which lead us to the conclusion that attribute
data under analysis are partially correlated. In order to carry out a
more consistent statistical independence test, it would be better to
consider a dataset with a higher number of instances. Moreover,
although some pairs of names for neuropsychological tests seem
to be similar (e.g. “Recall word list score” and “Word list recogni-
tion score”), all neuropsychological tests from both datasets
(CERAD and CAD) assess different dimensions of cognition, quality
of life and health of the patient, according to domain experts.
Hence, such unexpected correlation between tests could be
explained by the few number of instances available on the training
dataset.
Figs. 7 and 8 show the BN for diagnosis of dementia and AD
respectively, using patients' cases set from CERAD. Figs. 9–11 show
the BN for diagnosis of dementia, AD and MCI respectively, using
patients' cases set from CAD. The BN was drawn and evaluated
using the GeNIe/SMILE3 (Graphical Network Interface/Structural
Modeling Inference and Learning Engine) authoring and inference
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3 http://genie.sis.pitt.edu/.
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toolbox developed by Pittsburg University. As mentioned before,
the BN nodes stand for random variables that are associated to
dataset attributes, as shown in Tables 2 and 3 for CERAD and CAD
patients' dataset, respectively. In total, we propose ﬁve data-
oriented BNs: two BNs for diagnosis of dementia and AD using
CERAD patients' dataset, and three BNs for diagnosis of dementia,
AD and MCI using CAD patients' dataset (Figs. 7–11).
The following section evaluates the Bayesian learning through
performance measures.
5. Evaluation of results
Our BN was evaluated using performance measures for BN
classiﬁcation and measures for evaluating the BN robustness. The
classiﬁcation performance was evaluated using measures based on
discrimination and based on probability, as summarized in Table 5.
The discrimination measures evaluate how well the algorithm
differentiates between two classes. We used the area under
the ROC (Receiver Operating Characteristic) curve, known by the
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acronym AUC [79], and the F1-score obtained by the harmonic
mean of precision and recall [80]. The Bayesian classiﬁcation rule
is shown in equation below:
Z ¼ positive if PrðzposjEÞ ¼ max
i ¼ neg;pos
PrðzijEÞ; ð7Þ
where Z is the target node, which has two states for diagnosis,
positive or negative, as mentioned before.
Let a target variable Y takes values in [0, 1] and let yi be
classiﬁcation for a given case i. Let yi¼0 for negative state and
yi¼1 for positive state, and Prðyi ¼ 1Þ the probability of yi being 1.
So, the mean square error (MSE) for a dataset of n cases is deﬁned
as shown in equation below [81]:
MSE¼ 1
n
 ∑
n
i ¼ 1
½yiPrðyi ¼ 1Þ2 ð8Þ
The mean cross-entropy for n cases is calculated by Eq. (9) [82].
MXE¼ 1
n
 ∑
n
i ¼ 1
yi  log ½Prðyi ¼ 1Þð1yiÞ  log ½1Prðyi ¼ 1Þ ð9Þ
The performance measures were estimated based on the
k-folds cross-validation method [83]. Due to the number of cases
of the CAD dataset (314 cases after carrying out the oversampling
method), we used fourfolds for cross-validation, i.e., each
fold contained around 78 cases. Fig. 12 shows a comparison of
performance measures' results for BN and other well-known
classiﬁers found in the literature: (1) Näive Bayes [84], Logistic
regression model [85], Multilayer Perceptron ANN [82], Decision
table [83], Decision stump optimized by AdaboostM1 algorithm
[86] and J48 Decision tree [87]. Those classiﬁer implementations
were available in the WEKA data mining tool. Table 6 synthesizes
the parameters used by classiﬁers.
The purpose of the comparison of performance results shown
in Fig. 12 is to show that BN's performance is very close to other
well known classiﬁers, not to prove that they give best results. The
comments about the results will be addressed in Section 6.
We also compared the performance results for our BNs, shown
in the previous section, to corresponding BNs with structure
automatically discovered from the CAD dataset. Such comparison
results are shown in Fig. 13. The discovery method used for
estimating the BN structure and parameters was described by
Dash and Druzdzel [88]. Such method is based on the indepen-
dence test between dataset attributes, and applies the Greedy
Thick Thinning algorithm as a search method. Its implementation
is available on the GeNIe/SMILE authoring and inference toolbox
[89]. Such discovered topologies of BNs are shown in Figs. 14–16
for diagnosis of dementia, AD and MDI, respectively. We will
discuss their results in Section 6.
We carried out a sensitivity analysis for testing the robustness
of the results of our proposed BNs. Its purpose is to test how the
uncertainty in the output can be impacted by the evidence (partial
observations) in the input of BN [27]. Entropy is the most common
measure used in sensitivity analysis to evaluate uncertainty.
We measured the entropy H(X) in the target node X, where X
represents the probability of the patient to have the disease of
interest (positive for diagnosis of disease). The target node is
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labeled as “Diagnosis“ in the BN, as shown in Figs. 9–11, related to
diagnosis of dementia, AD and MCI, respectively
Table 7 shows the sensitivity analysis results using BNs mod-
eled from the CAD dataset. The entropy values were obtained in
the target node, calculated after performing the inference algo-
rithm using each piece of evidence alone. Then, the evidence was
grouped and sorted in decreasing order by entropy value, to
understand which evidence was more relevant to corresponding
positive or negative diagnosis for the disease. An evidence was
considered in a positive diagnosis group if PrðX ¼ PositivejEÞ40:5,
where E stands for corresponding evidence, otherwise it was
considered in a negative diagnosis group.
6. Discussion
Regarding the comparison of our BN performance results and
other well-known classiﬁers for the CERAD dataset (Fig. 12), the
best results for AUC were obtained by the Multilayer Perceptron
ANN classiﬁer (0.84 and 0.71 for dementia and AD, respectively).
Although ANNs have the ability to learn complex patterns directly
from observations, their reasoning process is inaccessible to
human understanding, which is hard for physicians to accept
the advice from CDSS without knowing the basis for the system
decision [90]. The ANNs are commonly treated as a black-box, not
offering a knowledge representation that allows domain experts
to criticize the diagnosis criteria. On the other hand, BN allows
the diagnostic criteria to be represented graphically using a
human-oriented causal diagram that facilitates the communica-
tion between domain experts and knowledge engineers. The
Decision Stump algorithm optimized by AdaboostM1 showed the
best results for F1-score, MSE and MXE.
Regarding the comparison of our BN performance results for
the CAD dataset, evaluating for AUC, Decision table and Decision
stump classiﬁers showed the best results for dementia (0.98). The
Multilayer Perceptron classiﬁer showed the best results for AD
(0.92). BN and Näive Bayes showed the best results for MCI (0.97),
which may indicate very promising results by the usage of
probabilistic causal models. As mentioned before, MCI is a clinical
condition often related to a preclinical stage of AD. Scientiﬁc
community efforts are driven by characterizing earliest stages of
AD, when its treatment is more efﬁcient. For F1-score, the best
results were obtained by Decision Table (0.95), Multilayer Percep-
tron (0.86) and BN (0.90) for dementia, AD and MCI, respectively.
For MSE and MXE, occurrences of best result were veriﬁed among
Decision stump, Multilayer Perceptron, Logistic regression and
Näive Bayes.
Comparing our proposed BN performance results to the auto-
matically discovered structure BN results, our BN showed results
very close to those obtained by BN with structure automatically
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Fig. 11. Bayesian network for diagnosis of MCI based on CAD patients' cases set.
Table 5
Performance measures used to evaluate the proposed BNs.
Performance measure Acronym Domain Best score
Area under ROC curve AUC [0, 1] 1
Harmonic mean of precision and recall F1 [0, 1] 1
Mean square error MSE [0, 1] 0
Mean cross-entropy MXE [0;1) 0
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discovered from the dataset, as shown in Fig. 13. Figs. 14–16 show
the BN automatically discovered from the CAD dataset for diag-
nosis of dementia, AD and MCI, respectively. We can notice that
the number of causal relationships in BN discovered structures is
higher than BNs with structure built manually (Figs. 9–11).
Furthermore, when evaluating the Bayesian structure discovered,
Dementia
CERAD
Alzheimer's 
Disease
CERAD
Dementia
ADC
Alzheimer's 
Disease
ADC
Mild
Cognitive
Impairment
ADC
Bayesian network 0.24 0.29 0.16 0.15 0.33 
NäiveBayes 0.18 0.23 0.07 0.21 0.09 
Logistic 0.17 0.23 0.07 0.25 0.34 
Multilayer perceptron 0.20 0.31 0.08 0.29 0.19 
Decision table 0.16 0.22 0.05 0.20 0.16 
Decision stump 0.02 0.00 0.07 0.14 0.17 
J48 0.17 0.24 0.06 0.24 0.17 
0.00 
0.10 
0.20 
0.30 
0.40 
Mean cross-entropy error (MXE) 
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Bayesian network 0.18 0.23 0.18 0.23 0.09 
NäiveBayes 0.24 0.29 0.13 0.16 0.15 
Logistic 0.22 0.28 0.11 0.17 0.00 
Multilayer perceptron 0.22 0.28 0.20 0.14 0.37 
Decision table 0.21 0.27 0.09 0.15 0.21 
Decision stump 0.17 0.22 0.07 0.14 0.12 
J48 0.23 0.27 0.09 0.18 0.21 
0.00 
0.10 
0.20 
0.30 
0.40 
Mean square error (MSE) 
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Bayesian network 0.78 0.65 0.94 0.82 0.92 
NäiveBayes 0.78 0.64 0.93 0.80 0.90 
Logistic 0.78 0.65 0.94 0.81 0.69 
Multilayer perceptron 0.78 0.66 0.92 0.86 0.79 
Decision table 0.79 0.66 0.95 0.77 0.78 
Decision stump 0.79 0.69 0.93 0.79 0.83 
J48 0.78 0.67 0.95 0.79 0.72 
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Fig. 12. Comparison of performance for BN and other well-known classiﬁers.
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it is possible to conceive some Bayesian nodes of symptoms and
neuropsychological tests being addressed as causes of the disease,
instead of consequences. For example, Fig. 14 reveals that demen-
tia is caused by the results of CDR (Clinical Dementia Rating),
because of the directed arc linking both BN nodes. However, this is
incorrect from the semantic point of view. There are many similar
examples in Figs. 15 and 16. Hence, BNs with structure built
manually are simpler and more readable for physicians and
domain experts than BNs discovered from dataset. Therefore,
despite showing a slight improvement of some performance
Table 6
List of parameters used by classiﬁers.
Classiﬁer Parameters description for performance evaluation
Näive Bayes Do not use a Kernel estimator for numerical attributes
Do not use a supervised discretization to convert numeric attributes to nominal ones
Logistic regression Logistic regression model with a ridge estimator. The missing values are replaced by nominal values. Maximum number of iterations equal to 1
Ridge value set in the log-likelihood equal to 10-8
Multilayer perceptron Do not add and connect up hidden layers in the network
Do not decrease the learning rate by the epoch number
Set the number of hidden layers¼(number of attributes þ number of classes)/2
Initial learning rate set to 0.3
Apply 0.2 as momentum to weights during the network updating
Normalize the nominal attributes to values between 1 and 1
Maximum number of epoch equal to 500
Allow the network to reset with a lower learning rate
The percentage size of validation set equal to 20
Decision table Use as validation the leave-one-out method
User accuracy as evaluation measure
Use Best-First algorithm as search method. The Best-First uses as heuristics method the greedy hill-climbing with backtracking
The maximum amount of backtracking is 5
Decision stump No parameters to conﬁgure
J48 Decision tree Do not use binary splits on nominal attributes when building the trees
The conﬁdence factor used for pruning (smaller values incur more pruning) set to 0.25
The minimum number of instances per leaf set to 2
Amount of data used for reduced-error pruning set to 3
Consider the sub-tree raising operation when pruning
Dementia Alzheimer's Disease
Mild 
Cognitive 
Impairment
BN built manually 0.96 0.86 0.97
BN discovered 0.94 0.89 0.96
0.60
0.70
0.80
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1.00
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Fig. 13. Comparison of performance measures results for BN with structure built manually and BN discovered from data.
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results, BN manually built structure might be more interesting for
maintaining the decision model readability for human experts.
Aiming at evaluating sensitivity analysis results (Table 7), we
asked a physician expert to evaluate each BN random variable in
terms of its corresponding relevance to the diagnosis of each
disease, dementia, AD and MCI, classifying each evidence into
three levels of relevance: (1) not relevant, (2) moderately relevant
and (3) very relevant. Then, we compared the neuropsychological
tests relevance classiﬁcation done by the physician expert to the
sensitivity analysis results. Neuropsychological tests CDR and VFT
were classiﬁed in both CDSS and by domain expert as highly
relevant for diagnosis of dementia. However, CDT and TMT were
classiﬁed as moderately relevant by the domain expert. Regarding
the diagnosis of AD, Pfeffer appeared in both classiﬁcations, CDSS
and by domain expert, as highly relevant. However, TMT and
IQCode were classiﬁed as moderately relevant by the domain
expert. All neuropsychological tests shown in the sensitivity
analysis for MCI diagnosis (TMT, CDT, Berg and Stroop) were
classiﬁed as moderately relevant by the domain expert. There
were no cases of total disagreement, such as a neuropsychological
test shown in sensitivity analysis as highly relevant and classiﬁed
as not relevant by the domain expert.
Furthermore, there were neuropsychological tests classiﬁed as
highly relevant and moderately relevant by domain expert, which,
however, were removed from BN due to its missing data ratio
exceeding an acceptable threshold. For example, the CamCog
(Cambridge Cognition) exam was classiﬁed as highly relevant by
domain expert and was excluded in a preprocessing data phase
due to its high missing data ratio (77%) in the dataset used. The
processing data stage of BN modeling was described in Section 4.
NPI (Neuropsychiatric Inventory), Digit Symbol, Digit Spam and
Complex Figure are other examples of neuropsychiatric exams
classiﬁed as moderately relevant for the diagnosis of diseases of
interest that were excluded due to their high missing data ratio.
Although these results are promising, we expect to obtain even
better results with a more complete patient dataset.
Regarding the statistical independence test, despite the neu-
ropsychological tests being different, we noticed some outliers in
the box plot shown in Fig. 6. The cause might be use of a training
database with too few instances. As future work, we will address a
statistical independence test considering more instances and a
more complete dataset.
7. Conclusion
This paper proposed a Bayesian Network (BN) decision model
for supporting diagnosis of dementia, AD and MCI. Such diseases
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are relevant due to global population the aging phenomenon, their
high prevalence among elderly population and their high impact
on the family, community and health care system. The proposed
decision model can be used to build clinical decision support
systems to diagnose such diseases.
The proposed decision model uses a probabilistic approach,
where symptoms, signs, test results and background information
are associated to random variables linked to each other, giving rise
to a causal diagram. BNs can be represented graphically, which
facilitates their readability by a domain expert. The proposed BN
modeling involved a domain expert elicitation and a learning
phase using an available dataset, which makes the decision model
more robust and reliable. BN has the ability to deal with partial
observations and uncertainty, makes the model suitable for clinical
context.
Our BN modeling was data-oriented, i.e., random variables
were derived from data attributes of patients' dataset. The BN
structure was built manually based on a three-level generic
BN structure. The probabilities distribution was estimated
from the dataset using the EM supervised learning algorithm.
The patients' datasets were provided by two different
institutions: CERAD and CAD. In total, ﬁve BNs were designed,
one for each disease and institution responsible for the patients'
dataset.
The main contribution of this paper was the development of a
decision model for clinical diagnosis using BN. When comparing
the performance results obtained by BN to other well-known
classiﬁers, BNs have shown better results for diagnosing MCI and
competitive results for dementia and AD. Another contribution
was a description of a BN modeling process. Such a process can be
extended to other disease domains.
As future work, we intend to revise the BN using a more
complete patients' dataset, including neuropsychological tests that
are relevant for diagnosis of the diseases of interest and that were
not available in the datasets used. Although it was not described in
this paper, the proposed decision model was used for developing a
web-based CDSS. We shall also extend the CDSS including other
diseases related to aging, using BN modeling.
Another goal is to deploy the CDSS in a clinical environment
and evaluate acceptance and feedback reported by physicians. The
adoption and more extensive use of CDSS depend on a number of
technological developments, including more widespread use of
EMRs (Electronic Medical Records) capabilities, development
of technologies for healthcare providers to share information
across entities, and cheaper, faster or more ﬂexible technology.
We are currently working in clinical data modeling using an open-
source and multi-level approach.
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